AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.
Agricola
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.
American Journal of Clinical Nutrition, Vol. 80, No. 6, 1536-1543, December 2004
© 2004 American Society for Clinical Nutrition

ORIGINAL RESEARCH COMMUNICATION

Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept1,2,3,4

Bert Bammens, Pieter Evenepoel, Kristin Verbeke and Yves Vanrenterghem

1 From the Department of Medicine, Division of Nephrology (BB, PE, and YV) and the Laboratory of Digestion and Absorption (KV), University Hospital Gasthuisberg, Leuven, Belgium

2 Presented in part at the American Society of Nephrology Annual Meeting, November 2003.

3 Supported by grant no. 1127602N from the Fonds voor Wetenschappelijk Onderzoek.

4 Address reprint requests to P Evenepoel, Department of Medicine, Division of Nephrology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. E-mail: pieter.evenepoel{at}uz.kuleuven.ac.be.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Protein malnutrition is a common finding in renal disease. Recently, we showed that impaired protein assimilation (digestion and absorption) may contribute to protein malnutrition in nondiabetic patients with chronic renal failure.

Objective: The aim of the present study was to evaluate whether these findings can be extended to the dialysis population. Moreover, relations with indexes of the malnutrition-inflammation-atherosclerosis (MIA) syndrome were investigated.

Design: Protein assimilation was evaluated in 24 healthy control subjects and in 40 patients with end-stage renal disease (ESRD; 14 treated with peritoneal dialysis and 26 with hemodialysis) by means of a [13C]protein breath test, quantification of the generation rate of p-cresol, or both methods. Both approaches provide reliable information on the efficiency of protein assimilation. Breath test results were expressed as the maximum percentage recovery per hour of the administered dose of 13C (%max) and as the cumulative percentage recovery at the end of the test (%cumend). Several indexes of nutritional status, inflammation, and atherosclerosis were assessed.

Results: Compared with the control subjects, ESRD patients had significantly lower breath-test derived indexes of protein assimilation [%max = 3.75 ± 0.30 compared with 4.90 ± 0.25, P = 0.006; %cumend = 12.41 (5.74–23.22) compared with 16.87 (9.42–22.99), P = 0.020] and a higher 24-h p-cresol generation rate corrected for dietary protein intake [3.89 (0.48–11.60) compared with 2.81 (0.21–11.20) mg p-cresol/g urea nitrogen; P = 0.028]. The presence of impaired protein assimilation was associated with indexes of the MIA syndrome.

Conclusion: Our study provides evidence that protein assimilation is impaired in ESRD patients. Moreover, this disorder is associated with the severity of the MIA syndrome.

Key Words: Malnutrition-inflammation-atherosclerosis syndrome • protein assimilation • p-cresol • breath test • end-stage renal disease


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Protein malnutrition, defined as low amounts of visceral and somatic proteins and a loss of lean body mass, is a common finding in patients with end-stage renal disease (ESRD). Depending on the variable measured, the prevalence of protein malnutrition ranges from 10% to 75% in hemodialysis (HD) patients and from 18 to 51% in peritoneal dialysis (PD) patients (1–6). Besides an inadequate dietary protein intake and increased protein losses, several other mechanisms have been shown to contribute to the impairment of nutritional status in ESRD. To date, most research has focused on the effect of disturbances in protein metabolism (breakdown, synthesis, and oxidation). The presence of metabolic acidosis has been shown to stimulate amino acid and protein catabolism by increasing the activity of the branched-chain ketoacid dehydrogenase, by impairing albumin synthesis, and by stimulating muscle protein breakdown through the ATP-ubiquitin-proteasome pathway (7–11). The loss of muscle protein in uremia is also caused by impaired action of anabolic hormones such as insulin and insulin-like growth factor I (11). Numerous studies highlight the high concentrations of inflammatory cytokines in ESRD patients (12–14) and consistently describe a relation between these indicators of inflammation on the one hand and impairment of nutritional status and accelerated atherosclerosis on the other (13–23). Although the exact mechanisms responsible for the interplay between the entities of the so-called malnutrition-inflammation-atherosclerosis (MIA) syndrome (15) are still being discovered, some in vitro and animal data suggest the involvement of the ATP-ubiquitin-proteasome pathway as well (10, 24, 25). Recently, we showed another mechanism that possibly contributes to the impaired nutritional status in uremic patients, notably the impairment of small intestinal protein assimilation (digestion and absorption) (26). In a group of nondiabetic, nonacidotic patients with severe renal insufficiency (glomerular filtration rate <30 mL · min–1 · 1.73 m–2), indicators of protein assimilation were significantly lower than in subjects with a glomerular filtration rate ≥60 mL · min–1 · 1.73 m–2. The question arising from these findings in nondialyzed patients is whether they can be extended to patients with ESRD treated with PD or HD. Moreover, in view of the MIA syndrome (15), it is worthwhile to investigate possible relations between indexes of protein assimilation and indexes of malnutrition, inflammation, and atherosclerosis. It was the aim of the present study to answer these questions by studying protein assimilation by means of breath-test technology in healthy control subjects and in ESRD patients treated with PD or HD. Furthermore, the amount of protein escaping digestion and absorption in the small intestine was evaluated indirectly by estimating the generation of the specific bacterial fermentation metabolite p-cresol from urinary and dialytic removal (26–28).


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Study design
Protein assimilation was evaluated in a cross-sectional observational design by means of breath-test technology and an estimation of daily p-cresol generation. Furthermore, several indexes of the MIA syndrome were measured. The study was approved by the ethical committee of the University Hospital Gasthuisberg, and informed consent was obtained from all subjects.

[13C]Protein breath test
Fifty subjects were included in this part of the study: 24 control subjects and 26 ESRD patients (14 treated with PD and 12 treated with HD). Demographic data of the study participants are shown in Table 1Go. None of the subjects had a history of gastrointestinal disease or surgery, hepatic disease, or diabetes mellitus; used drugs known to influence gastrointestinal motility (prokinetics or antiemetics) or protein assimilation (prebiotics, probiotics, antibiotics, or inhibitors of gastric acid secretion) during the preceding 3 mo; or had metabolic acidosis as defined by a serum bicarbonate concentration of ≤20 mEq/L. The control subjects comprised medical students (n = 12) and members of an association of retired persons (n = 12). They had no renal, metabolic, cardiovascular, gastrointestinal, or respiratory disease. The causes of renal disease in the patients included polycystic kidney disease (n = 6), glomerular disease (n = 13), tubulointerstitial disease (n = 4), and unknown etiologies (n = 3). PD patients were treated with standard lactate-buffered glucose solutions (Dianeal; Baxter, Lessines, Belgium) via continuous ambulatory PD (n = 6) or automated PD (n = 8) for ≥3 mo. In 4 PD patients, the polyglucose icodextrin (Extraneal; Baxter) was used during one long dwell per day. No amino acid-containing or bicarbonate-buffered solutions were applied. Residual renal function (RF) in the PD patients was 4.7 (0–9.1) mL · min–1 · 1.73 m–2. HD patients were treated 3 times, 4 h/wk, with maintenance high-flux HD (n = 7) or postdilution hemodiafiltration (n = 5) for ≥3 mo. Their mean residual RF was 0.2 (0–1.0) mL · min–1 · 1.73 m–2.


View this table:
[in this window]
[in a new window]
  		TABLE 1 Subject characteristics1

 
Protein assimilation was evaluated after the subjects fasted overnight for ≥12 h by means of a [13C]protein breath test as described earlier (26, 28). The solid test meal (being a pancake) consisted of 7.5 g lyophilized [13C]leucine-labeled egg white, 17.2 g lyophilized [13C]leucine-labeled egg yolk, 3.75 g lyophilized unlabeled egg white, 3 g milk powder, 7 g sugar, 17 g flour, 130 mL water, and 5 g butter. The caloric content of the meal amounted to 327.4 kcal (18.67 g protein, 6.15 g fat, and 36.8 g carbohydrates). Subjects were asked to consume the meal together with 200 mL water within 15 min. Breath samples for the detection of 13CO2 were collected twice immediately before ingestion of the test meal and at 15-min intervals for a period of 6 h thereafter.

Breath was collected by blowing air through a straw in a small tube called an exetainer (Europa Scientific, Crewe, United Kingdom). The 13C content of the breath was determined by online gas chromatographic purification-isotope ratio mass spectrometry (Automated Breath 13C Analyzer-New Technology 20-20 Stable Isotope Analyzer; Europa Scientific). The {delta} values obtained by isotope ratio mass spectrometry were converted to percentage 13C recovery per hour (%dose/h) of the initial amount administered according to calculations described in detail by Ghoos et al (29). Cumulative percentages of label recovery (%cum) were calculated by means of the trapezoidal rule. From these data, the following indexes of protein assimilation were derived: the maximum percentage of the administered dose of 13C excreted per hour (%max) and the cumulative percentage of the administered dose of 13C recovered in the breath at the end of the test (%cumend).

p-Cresol generation rate
In a steady-state situation, total daily elimination of a molecule equals its daily generation. p-Cresol is a unique bacterial fermentation metabolite of tyrosine in the colon. Because most of the produced p-cresol is absorbed by the colonic mucosa, urinary output of the molecule reflects its colonic generation in nondialyzed subjects (26, 27, 30, 31). When dealing with ESRD patients, however, the elimination of p-cresol through the dialytic procedure also has to be taken into account. All control subjects (n = 24) and PD patients (n = 14) performed a 24-h urine collection. The collection bottles were refrigerated (0–4°C) at the participant's home to prevent bacterial growth and brought to the laboratory within hours of the time that the collection ended. During the same 24-h period, peritoneal drainage was collected by the PD patients. In 14 HD patients, total dialysate was collected in a 300-L polyethylene vessel during a midweek dialysis session. Although they were not the same patients as those who underwent the breath-test study, they met the same eligibility criteria, and their demographic variables were nearly identical (first set of values is for the 14 HD patients): age, 72 y (range: 42–82 y) compared with 64 y (49–80 y); sex distribution, 7 males compared with 9 males; body weight, 62.1 ± 2.0 compared with 65.5 ± 4.1 kg; body mass index (BMI; in kg/m2), 22.3 (17.6–26.8) compared with 22.0 (17.7–35.0); and residual RF, 0.1 (0–6.4) compared with 0.2 (0–1.0) mL · min–1 · 1.73 m–2 (two-sided P value > 0.3 in all comparisons). They were all treated trice weekly with maintenance high-flux HD. If not anuric (n = 7), the patients also performed an interdialytic (44 h) urine collection. Collected volumes of urine and dialysate were vigorously stirred, weighed, and sampled. All samples were stored at –80°C until analyzed. The total weekly elimination of the solute was calculated on the basis of measured p-cresol concentrations and volumes. The results were then expressed as amounts eliminated per 24 h. As a reflection of dietary protein intake, 24-h elimination of urea nitrogen was calculated as well by using the same approach (32).

Indexes of the MIA syndrome
The anthropometric indicators of nutritional status measured were body weight (kg) and BMI, calculated from height (kg) and body weight (m2). Dietary protein (g · kg–1 · d–1) and energy intake (kcal · kg–1 · d–1) were evaluated by computer calculations based on a 7-d dietary record. Serum C-reactive protein (CRP) concentrations (mg/L) were measured as an index of inflammation. On the basis of a review of the medical records, comorbidity was assessed by using the method described by Davies et al (33). In brief, 7 categories of comorbid conditions were scored 1 (present) or 0 (absent). The total sum of scores was used to determine the grade of comorbidity. Grade 0 (low risk) is a score of 0, grade 1 (medium risk) is a score of 1–2, and grade 2 (high risk) is a cumulative score of ≥3. Subjects scoring 1 in the categories "ischemic heart disease" and "peripheral vascular disease" were considered to have atherosclerotic disease. Serum albumin (g/L) and the Malnutrition-Inflammation Score (MIS) were determined as indicators of both nutritional status and inflammation. The latter comprehensive scoring system, with a possible range of from 0 to 30, combines components of the Subjective Global Assessment (34) and 3 additional elements (serum albumin, total-iron-binding capacity, and BMI) (23).

Biochemical analyses
Serum albumin, total-iron-binding capacity, CRP, serum bicarbonate, serum creatinine, and serum urea nitrogen concentrations were measured by using standard laboratory techniques. p-Cresol was analyzed by gas chromatography-mass spectrometry (GC-MS) technology. Five hundred microliters of serum was diluted with 450 µL water. The pH of a 950-µL sample (diluted serum, urine, or dialysate) was adjusted to pH 1 with concentrated H2SO4, and the solution was heated to 90°C for 30 min. After a cooling-down period to ambient temperature, 50 µL 2,6-dimethylphenol solution (20 mg/100 mL) was added as internal standard. One milliliter ethyl acetate was added for the extraction of p-cresol. The solution was well mixed for 30 s and centrifuged at 1583 x g (3300 rpm) for 20 min. Then, 500 µL of the supernatant fraction was dried over anhydrous sodium sulfate, and 100 µL of the resultant sample was transferred to the GC-MS apparatus (Trace GC-MS; Thermofinnigan, San José, CA) for automatic splitless injection of 0.5 µL. The analytic column used was 30 m (length) x 0.32 mm (internal diameter) and had a film thickness of 1 µm (AT5-MS; Alltech, Deerfield, IL). Helium GC grade was used as a carrier gas with a constant flow of 1.3 mL/min. The oven was programmed from 75°C (isotherm for 5 min) to 280°C at 15°C/min. After separation, p-cresol was identified by MS (electron impact full scan mode with mass-to-charge ratios of from 59 to 590 at 2 scan/s). Quantitative results were obtained by the internal standard method and calculated as concentrations. The R2 of the calibration line was 0.998. The method has low intra- and interassay variabilities (CVs of 3.33% and 5.30%, respectively). It is able to detect total p-cresol concentrations ranging from 0.15 to 60 mg/L; the extraction efficiency is 91.5%.

(Residual) RF was estimated by calculating the arithmetic mean of renal urea nitrogen and creatinine clearance. Values were normalized for body surface area (BSA) by multiplying by 1.73/BSA(m2) and were expressed as mL · min–1 · 1.73 m–2. BSA was calculated from the formula of Haycock et al (35):

Correction of 13C data for background enrichment of breath
We previously reported on the possible influence of changes in background 13C enrichment of breath carbon dioxide due to the high 13C content of dialysis fluids in PD patients (36, 37). In the present study, this problem was accounted for by performing all breath tests in PD patients after the peritoneal cavity was drained. To correct for the influence of the preceding dwell, breath samples for detection of background 13CO2 were collected by each PD patient under identical test conditions (ie, after an overnight fast of ≥12 h and after drainage of the peritoneal cavity) but without ingestion of any labeled substrate. These background data were used to correct [13C]protein breath-test results. In HD patients, breath tests were performed on a nondialysis day because also in this patient group interference of dialysate background enrichment occurs. Moreover, changes in the bicarbonate pool can be expected during and immediately after a dialysis session, which further emphasizes the importance of performing breath tests on a nondialysis day.

Statistical analysis
Data are expressed as means ± SEMs if normally distributed or as medians and ranges otherwise. The normality of distributions was assessed by Kolmogorov-Smirnov and Cramer-von Mises tests. Differences between groups were evaluated by using unpaired t tests, Mann-Whitney U tests, and parametric or nonparametric one-way analysis of variance where appropriate. Categorical data were compared by the chi-square tests for association. Spearman correlation coefficients were calculated in the total group of subjects to assess possible associations between different variables. The variables "Davies grade" and "atherosclerotic disease" were considered as ordinal numerical variables for this purpose. P values < 0.05 were considered significant. The SAS version 8.02 (SAS Institute, Cary, NC) software program was used for the statistical analysis.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
[13C]Protein breath test
The mean 13C excretion curves in control subjects and ESRD patients, expressed as %dose/h and %cum obtained after ingestion of the [13C]protein test meal, are depicted in Figure 1Go. The curves for the ESRD patients are flattened compared with those observed for the control subjects. Breath test-derived indexes of protein assimilation (%max and %cumend) were significantly lower in the ESRD patients than in the control subjects. (Table 2Go)



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 1. Mean 13C enrichment of breath carbon dioxide expressed as a percentage of the administered dose of [13C]leucine per hour and as a cumulative percentage (%cum) in control subjects ({square}, n = 24) and patients with end-stage renal disease ({diamondsuit}, n = 26) after ingestion of the [13C]protein meal. Bars represent 95% CIs.

 

View this table:
[in this window]
[in a new window]
  		TABLE 2 [13C]Protein breath test1

 
p-Cresol generation rate
As illustrated in Table 3Go, the difference in 24-h elimination of p-cresol between the ESRD patients and the control subjects was not statistically significant. When the data were expressed per gram of urea nitrogen eliminated, as a correction for dietary protein intake, the difference was significant.


View this table:
[in this window]
[in a new window]
  		TABLE 3 p-Cresol generation rate1

 
Indexes of the MIA syndrome
Data on nutritional status, inflammation, and atherosclerosis are shown in Table 4Go. Anthropometric measures did not differ significantly between the 2 groups, although there was a trend for a lower BMI in the ESRD patients. No significant difference in protein intake was seen between the groups. Daily energy intake, however, was significantly lower in the patient group than in the control subjects. Significantly higher serum concentrations of CRP were seen in the ESRD patients than in the control subjects. Comorbidity, evaluated by Davies score and comorbidity grade, was significantly higher in the ESRD patients as was the frequency of atherosclerotic disease. Serum albumin concentrations were significantly lower and MIS was significantly higher in the ESRD patients than in the control subjects.


View this table:
[in this window]
[in a new window]
  		TABLE 4 Indexes of the malnutrition-inflammation-atherosclerosis syndrome1

 
Correlations
As shown in Table 5Go, both %max and %cumend were significantly related with serum creatinine, RF, Davies score, Davies grade, and the presence of atherosclerotic disease. In addition, %max was significantly correlated with serum urea nitrogen, serum p-cresol, CRP, and MIS.


View this table:
[in this window]
[in a new window]
  		TABLE 5 Spearman correlation coefficients for indexes of protein assimilation1

 
Data on both the p-cresol generation rate and the other variables were available in only 38 subjects (ie, 24 control subjects and 14 ESRD patients). Within this group, the 24-h elimination of p-cresol as well as the elimination of p-cresol/urea nitrogen correlated significantly with serum urea nitrogen, serum creatinine, serum p-cresol, RF, CRP, and serum albumin. (Table 5Go)

Because there was a significant age difference between the groups (Table 1Go), we evaluated the relations between age and all the other measured variables. Significant correlations with age were found only for serum urea nitrogen, serum creatinine, RF, BMI, CRP, Davies score, Davies grade, serum albumin, and MIS (Table 6Go) No correlations were found between age and [13C]protein breath test-derived indexes or between age and the p-cresol generation rate. (Spearman correlation coefficients shown in last row of Table 5Go, all P values > 0.150.)


View this table:
[in this window]
[in a new window]
  		TABLE 6 Spearman correlation coefficients for indexes of the malnutrition-inflammation-atherosclerosis syndrome1

 
As illustrated in Table 6Go, significant relations were found between RF indexes (serum urea nitrogen, serum creatinine, serum p-cresol, and RF) and indexes of the MIA syndrome. In view of the correlations found between indexes of protein assimilation and indexes of the MIA syndrome (Table 5Go), a comparison was made between ESRD patients with a MIS below and above the median value of 6. As denoted in Table 7Go, the latter were older and had a higher Davies score and comorbidity grade than did those with a MIS <6. Their serum concentrations of urea nitrogen, creatinine, and CRP were higher as well, whereas RF was lower. Moreover, the ESRD patients with a MIS >6 had lower breath test-derived indexes of protein assimilation than did their counterparts with a MIS <6 (%max = 3.24 ± 0.37 compared with 4.23 ± 0.43, one-sided P = 0.045; %cumend = 12.11 (5.74–19.84) compared with 12.88 (8.91–23.22), one-sided P = 0.085). The high-MIS group consisted predominantly of patients treated with HD (n = 10, P = 0.0016).


View this table:
[in this window]
[in a new window]
  		TABLE 7 Comparison of end-stage renal disease patients with a high or low Malnutrition-Inflammation Score (MIS)1

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The findings of this cross-sectional observational study indicate that small intestinal protein assimilation (digestion and absorption) is impaired in ESRD patients. Moreover, indexes of protein assimilation were related to indexes of the MIA syndrome. Small intestinal protein assimilation was studied by 2 different approaches. First, the validated [13C]protein breath test was used (26, 28); background bias due to the dialysis procedure was taken into account where appropriate. The mean 13CO2 excretion curve, expressed as %dose/h, was flattened in the ESRD patients as compared with that in the control subjects and mathematically derived indexes of protein assimilation (%max and %cumend) were significantly lower in the former group (Figure 1Go and Table 2Go). Second, daily colonic generation of the bacterial fermentation metabolite p-cresol, corrected for dietary protein intake, was higher in the ESRD patients than in the control subjects (Table 3Go). This is a reflection of the higher amount of protein escaping small intestinal digestion and absorption in the former (27). We measured the total daily elimination of p-cresol to estimate its generation rate. An essential assumption for this approach is the steady state situation. We believe that this assumption is applicable to our study population, because subjects in whom recent changes in the colonic flora could be expected were excluded from the study. Moreover, the participants were all consuming their usual diets, which minimized the possible influence of dietary changes on p-cresol generation.

In a recent study, using the same methodology, we found evidence for impaired protein assimilation in nondialyzed uremic patients (26). The present data extend these findings to the dialysis population. Several gastrointestinal abnormalities have been reported in dialyzed as well as in nondialyzed uremic patients, including gastrointestinal motility disorders (38, 39), small-bowel bacterial overgrowth (40, 41), gastric hypochlorhydria (30), and pancreatic abnormalities (42, 43). Each of them could theoretically disturb protein digestion or absorption. The clinical relevance of these abnormalities and their pathogenetic role in the impairment of protein assimilation, however, remain to be elucidated.

An association between symptoms of malnutrition, inflammation, and atherosclerosis in uremic patients was described recently (15). The existence of this so-called MIA syndrome was confirmed in several publications (5, 19, 20, 23, 44). Because digestion and subsequent absorption of dietary protein play a pivotal role in the maintenance of a neutral nitrogen balance, disturbances in these processes may contribute to the impaired nutritional status seen in uremic patients. Hence, as a secondary endpoint of our study, we investigated the relations between indexes of protein assimilation and indexes of the abovementioned MIA syndrome. In a correlation analysis, breath test-derived indexes of protein assimilation were associated with comorbidity, atherosclerosis, and inflammation. p-Cresol generation rate correlated significantly with CRP and serum albumin (Table 5Go). Furthermore, although not uniformly significant, lower breath test-derived indexes of protein assimilation were observed in the ESRD patients with a higher MIS, most of whom were treated with HD, than in those with a lower MIS. The latter finding suggests that the above correlations are not simply a statistical consequence of covarying differences between control subjects and ESRD patients in protein assimilation (Tables 2Go and 3Go) and indexes of the MIA syndrome (Table 4Go). Although our observations do not prove causality, they certainly suggest that impairment of protein assimilation might be one of the factors playing a role in the MIA syndrome (15). Although the sample size of our study does not allow for an adequate multivariate analysis to address this issue, (residual) RF seems to play a key role in the interplay between the MIA indexes and protein assimilation. Both indexes of protein assimilation and indexes of the MIA syndrome were strongly related to (residual) RF. Also, when the analysis was confined to the ESRD patients, a significantly lower residual RF was noted in the patients with a higher MIS and lower breath test-derived indexes of protein assimilation (Table 7Go). This may not be a surprise considering the evidence of lower residual RF as a cardiovascular risk factor and the relation between RF, inflammatory indexes, and nutritional indexes described by others (45–48).

Some methodologic issues have to be addressed. First, to minimize metabolic interference with the breath tests performed in this study, we excluded patients with diabetes mellitus, hepatic failure, or metabolic acidosis (7–9, 49, 50). Hence, on the basis of our findings, no conclusions can be drawn with regard to uremic patients belonging to these subpopulations. Second, although daily generation of p-cresol reflects the amount of protein escaping digestion and absorption in the small intestine (26, 27), this is not the only determining factor. As stated earlier, daily p-cresol generation is known to be influenced by dietary protein intake. Both the quantity and quality of the protein may be important in this regard. We normalized our data for the quantity of dietary protein. Because subjects were consuming a free diet, however, we were not able to evaluate the possible effect of qualitative differences. Other factors involved are the amount of (fermentable) dietary fiber, characteristics of the bacterial flora, and colonic transit time. Nevertheless, taking into account the breath-test data, which are not influenced by these factors, we consider the p-cresol generation rate as a valid, although rather crude, estimate of the amount of protein escaping small intestinal assimilation.

Finally, because of the inclusion and exclusion criteria and the fact that breath-test performance requires full cooperation of the tested subjects, most participants in the present study were in good clinical condition. This was reflected by the relatively mild indexes of the MIA syndrome. As compared with the mean values in our center's total dialysis population, the ESRD patients in the present study were significantly younger, had significantly lower Davies scores and grades, had a lower prevalence of atherosclerotic disease, had higher serum albumin concentrations, had lower CRP concentrations, and had higher daily protein intakes (data not shown; two-sided P value < 0.05 in all comparisons). From our correlation data, it can be speculated that the findings of impaired protein assimilation would have been more pronounced in sicker patients.

In conclusion, our study provides evidence that protein assimilation is impaired in ESRD patients. Although the exact pathogenesis of the disorder has to be clarified by further investigation, its presence seems to be associated with the severity of the MIA syndrome.


   ACKNOWLEDGMENTS
 
We acknowledge M Dekens, C Dewit, N Gorris, S Rutten, R Servaes, and L Swinnen for providing excellent technical assistance and D Kuypers and B Maes for providing scientific comments and reviewing the manuscript.

BB and PE developed the idea for the study and were involved in the planning and design of the study. BB, PE, KV, and YV were involved in the interpretation of the results and writing of the manuscript. BB collected the data and was responsible for the data analysis, interpretation of the data, writing of the first draft, and integration of the comments from the coauthors. None of the authors had a conflict of interest.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Kalantar-Zadey K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001;38:1343–50.[Medline]
  2. Bergström J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int 1993;43(suppl 40):S39–50.
  3. Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 1998;53:773–82.[Medline]
  4. Burrowes JD, Cockram DB, Dwyer JT, et al. Cross-sectional relationship between dietary protein and energy intake, nutritional status, functional status, and comorbidity in older versus younger hemodialysis patients. J Renal Nutr 2002;12:87–95.[Medline]
  5. Qureshi AR, Alvestrand A, Divino-Filho JC, et al. Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002;13:S28–36.[Abstract/Free Full Text]
  6. Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 2002;40:307–14.[Medline]
  7. Price SR, Mitch WE. Metabolic acidosis and uremic toxicity: protein and amino acid metabolism. Semin Nephrol 1994;14:232–7.[Medline]
  8. Mitch WE, Price SR, May RC, Jurkovitz C, England BK. Metabolic consequences of uremia: extending the concept of adaptive responses to protein metabolism. Am J Kidney Dis 1994;23:224–8.[Medline]
  9. Pickering WP, Price SR, Bircher G, Marinovic AC, Mitch WE, Walls J. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 2002;61:1286–92.[Medline]
  10. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335:1897–905.[Free Full Text]
  11. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999;276:C1132–8.[Medline]
  12. Panichi V, Migliori M, De Pietro S, et al. C-Reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002;91:594–600.[Medline]
  13. Yukiko K, Masato K, Takashi Y, Kunihiko M, Ikuo H, Hiromichi K. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93–100.[Medline]
  14. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int 2002;61(suppl 80):S103–8.
  15. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899–911.[Medline]
  16. Guarnieri G, Antonione R, Biolo G. Mechanisms of malnutrition in uremia. J Renal Nutr 2003;13:153–7.[Medline]
  17. Riella MC. Malnutrition in dialysis: malnourishment or uremic inflammatory response? Kidney Int 2000;57:1211–32.[Medline]
  18. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953–60.[Free Full Text]
  19. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella MC, Stenvinkel P. Inflammation, malnutrition and atherosclerosis in ESRD: a global perspective. Blood Purif 2002;20:454–8.[Medline]
  20. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant 2002;17:28–31.[Abstract/Free Full Text]
  21. Kaysen GA. Malnutrition and the acute-phase reaction in dialysis patients—how to measure and how to distinguish. Nephrol Dial Transplant 2000;15:1521–4.[Free Full Text]
  22. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-Inflammation Complex Syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003;45:864–81.
  23. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001;38:1251–63.[Medline]
  24. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. J Am Soc Nephrol 2002;13(suppl 1):S22–7.[Abstract/Free Full Text]
  25. Du J, Mitch WE, Wang X, Price SR. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-Kß. J Biol Chem 2000;275:19661–6.[Abstract/Free Full Text]
  26. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003;64:2196–203.[Medline]
  27. Evenepoel P, Claus D, Geypens B, et al. Amount and fate of egg protein escaping assimilation in the small intestine of humans. Am J Physiol 1999;277:G935–43.[Medline]
  28. Geboes KP, Bammens B, Luypaerts A, et al. Validation of a new test meal for a protein digestion breath test in humans. J Nutr 2004;134:806–10.[Abstract/Free Full Text]
  29. Ghoos Y, Geypens B, Maes B, Hiele M, Vantrappen G, Rugeerts P. Breath tests in gastric emptying and transit studies: technical aspects of 13CO2-breath tests. In: Janssens J, ed. Progress in understanding and management of gastro-intestinal motility disorders. Belgium, KULeuven, 1993:169–80.
  30. Evenepoel P, Claus D, Geypens B, et al. Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. Aliment Pharmacol Ther 1998;12:1011–9.[Medline]
  31. Bone E, Tamm A, Hill M. The production of urinary phenols by the gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr 1976;29:1448–54.[Abstract/Free Full Text]
  32. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58–65.[Medline]
  33. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002;17:1085–92.[Abstract/Free Full Text]
  34. Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987;11:8–13.[Abstract]
  35. Haycock G, Schwartz G, Wisotsky D. Geometric method for measuring body surface area: a height-weight formula validated in infants, children and adults. J Pediatr 1978;93:62–6.[Medline]
  36. Maes BD, Evenepoel P, Geypens B, Rutgeerts P, Ghoos Y. Gastric emptying in renal failure patients using the 13C-octanoic acid breath test: facts and artifacts. Perit Dial Int 2002;22:732–5.[Free Full Text]
  37. Bammens B, Evenepoel P, Rutgeerts P, Ghoos Y, Maes B. 13C-breath tests in peritoneal dialysis patients: influence of dialysis fluids. Eur J Gastroenterol Hepatol 2003;15: 931–2.[Medline]
  38. Brown-Cartwright D, Smith HJ, Feldman M. Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis Gastroenterology 1988;95:49–51.[Medline]
  39. Stompor T, Hubalewska-Hola A, Staszczak A, Sulowicz W, Huszno B, Szybinski Z. Association between gastric emptying rate and nutritional status in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 2002;22:500–5.[Abstract/Free Full Text]
  40. Strid H, Simrén M, Stotzer PO, Ringström G, Abrahamsson H, Björnsson ES. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion 2003;67:129–37.[Medline]
  41. Simenhoff ML, Saukkonen JJ, Burke JF, et al. Importance of aliphatic amines in uremia. Kidney Int 1978;13(suppl 8):S16–9.
  42. Abu-Alfa A, Ivanovich P, Mujais SK. Uremic exocrine pancreopathy. Nephron 1988;48:94–100.[Medline]
  43. Ventrucci M, Cipolla A, Middonno M, et al. Impaired fecal elastase excretion in uremic pancreopathy. Dig Dis Sci 2000;45:2265–9.[Medline]
  44. Wang AYM, Woo J, Wang M, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001;12:1927–36.[Abstract/Free Full Text]
  45. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001;38:85–90.[Medline]
  46. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003;18:590–7.[Abstract/Free Full Text]
  47. Pecoits-Filho R, Heimbürger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212–8.[Medline]
  48. Wang AY, Sea MM, Ip R, et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001;12:2450–7.[Abstract/Free Full Text]
  49. Halvatsiotis PG, Turk D, Alzaid A, Dinneen S, Rizza RA, Nair KS. Insulin effects on leucine kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab 2002;15:136–42.[Medline]
  50. McCullough AJ, Mullen KD, Tavill AS, Kalhan AD. In vivo differences between the turnover rates of leucine and leucine's ketoacid in stable cirrhosis. Gastroenterology 1992;103:571–8.[Medline]
Received for publication April 30, 2004. Accepted for publication July 19, 2004.




This article has been cited by other articles:


Home page
 CJASNHome page
N. M. Pham, N. S. Recht, T. H. Hostetter, and T. W. Meyer
Removal of the Protein-Bound Solutes Indican and P-Cresol Sulfate by Peritoneal Dialysis
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 85 - 90.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. E Suliman, A R. Qureshi, P. Stenvinkel, R. Pecoits-Filho, P. Barany, O. Heimburger, B. Anderstam, E. Rodriguez Ayala, J. C Divino Filho, A. Alvestrand, et al.
Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease
Am. J. Clinical Nutrition, August 1, 2005; 82(2): 342 - 349.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.
Agricola
Right arrow Articles by Bammens, B.
Right arrow Articles by Vanrenterghem, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS